' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 11 Researches
7.7
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin K₂ (as MK-7 [Menaquinone-7])
90 mcg
†
Top Medical Research Studies
8
Vitamin K2 inhibits cancer cell growth
Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4.
Relevant score indicates strong significance
We investigated how vitamin K2 (VK2) influences the growth of cancer cells, particularly focusing on hepatocellular carcinoma (HCC). Our study centered on the interaction between VK2 and a protein known as HSD17B4, which is known to promote cancer cell proliferation. Previous research had shown that VK2 can bind to this protein, but we aimed to uncover the specific mechanisms behind its potential anti-cancer effects.
Through our experiments, we observed that VK2 can inhibit the growth of HCC cells by binding directly to HSD17B4. Interestingly, VK2 did not alter the expression levels of HSD17B4, which suggests that its impact on cell growth is due to other mechanisms. Specifically, we found that VK2 impedes the activation of important signaling pathways, including AKT and MEK/ERK, which play a critical role in cancer cell proliferation. As a result, this inhibition leads to decreased activity of another protein, STAT3, associated with cancer growth.
Moreover, VK2 demonstrated the ability to suppress the growth of transplanted tumors that were influenced by HSD17B4. These findings not only shed light on VK2's mechanism of action, but they also offer promising insights into its potential role in preventing or treating HCC in future applications.
Through our experiments, we observed that VK2 can inhibit the growth of HCC cells by binding directly to HSD17B4. Interestingly, VK2 did not alter the expression levels of HSD17B4, which suggests that its impact on cell growth is due to other mechanisms. Specifically, we found that VK2 impedes the activation of important signaling pathways, including AKT and MEK/ERK, which play a critical role in cancer cell proliferation. As a result, this inhibition leads to decreased activity of another protein, STAT3, associated with cancer growth.
Moreover, VK2 demonstrated the ability to suppress the growth of transplanted tumors that were influenced by HSD17B4. These findings not only shed light on VK2's mechanism of action, but they also offer promising insights into its potential role in preventing or treating HCC in future applications.
Read More
8
Vitamin K2 enhances cancer treatment
Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
Significant combination treatment findings
We explored the potential of Vitamin K2 (VK2) as a treatment option for chronic myeloid leukemia (CML), particularly in cases where cells have developed resistance to common therapies. The study focused on how VK2 interacts with asciminib, a specialized drug that targets specific challenges faced in treating this type of cancer.
Using a variety of CML cell lines, including those resistant to other medications, we observed that combining VK2 with asciminib led to greater levels of cell inhibition. This combination not only improved cell death rates but also activated key indicators of cellular distress, like caspase activity, which is associated with apoptosis (programmed cell death).
While VK2 alone had shown some anticancer promise, its partnership with asciminib unveiled an enhanced efficacy, making the duo a compelling consideration for those resistant to traditional ABL tyrosine kinase inhibitors (TKIs). This finding holds significant promise for improving treatment outcomes for patients battling resistance in CML.
Using a variety of CML cell lines, including those resistant to other medications, we observed that combining VK2 with asciminib led to greater levels of cell inhibition. This combination not only improved cell death rates but also activated key indicators of cellular distress, like caspase activity, which is associated with apoptosis (programmed cell death).
While VK2 alone had shown some anticancer promise, its partnership with asciminib unveiled an enhanced efficacy, making the duo a compelling consideration for those resistant to traditional ABL tyrosine kinase inhibitors (TKIs). This finding holds significant promise for improving treatment outcomes for patients battling resistance in CML.
Read More
8
Vitamin K2-7's potential in cancer
Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities.
Benefits in cancer treatment uncertain
We examined the effects of vitamin K2-7, also known as menaquinone-7, on cancer, focusing on its mechanisms and overall health benefits. Our analysis highlighted that K2-7 may help suppress cancer cell growth through several interesting pathways, including cell-cycle arrest and promoting apoptosis, which is essentially programmed cell death that is crucial for eliminating harmful cells.
Moreover, we observed K2-7's ability to influence certain inflammatory markers, indicating it may play a role in reducing inflammation associated with various cancers. These mechanisms suggest that vitamin K2-7 could be a beneficial supplement alongside traditional cancer treatments, although further research is necessary to fully understand its isolated effects.
While the promising results lean towards its potential, it's essential to note that there have been no definitive claims that vitamin K2-7 is a standalone treatment. Instead, it seems to act as a supportive agent, working alongside other therapies to enhance health outcomes in cancer patients. Overall, we encourage more clinical trials to clarify its role and effectiveness in cancer treatment protocols.
Moreover, we observed K2-7's ability to influence certain inflammatory markers, indicating it may play a role in reducing inflammation associated with various cancers. These mechanisms suggest that vitamin K2-7 could be a beneficial supplement alongside traditional cancer treatments, although further research is necessary to fully understand its isolated effects.
While the promising results lean towards its potential, it's essential to note that there have been no definitive claims that vitamin K2-7 is a standalone treatment. Instead, it seems to act as a supportive agent, working alongside other therapies to enhance health outcomes in cancer patients. Overall, we encourage more clinical trials to clarify its role and effectiveness in cancer treatment protocols.
Read More
Most Useful Reviews
8.8
Promotes health overall
I take MK-7 daily to prevent various health issues, including supporting bone density and fighting cancer. I learned about its benefits on the Dr. Oz show, and it has become an essential part of my routine. I appreciate the many advantages it offers to my overall well-being.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 11 Researches
7.7
9.5
Vitamin K2, venetoclax synergy in AML
Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway.
Moderate relevance to isolated effects
We observed how vitamin K2 (VK2) could play a significant role in enhancing the effectiveness of a common treatment for acute myeloid leukemia (AML) called venetoclax (VEN). In our investigation, older patients diagnosed with AML showed promising responses to a treatment combination of VEN and another drug, azacitidine (AZA), alongside daily VK2 intake. Remarkably, we noted a complete response rate of about 79% among patients taking VK2, highlighting the potential of VK2 to improve treatment outcomes.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Read More
8
VK2 enhances CML treatment efficacy
Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity.
Combination therapy limits cancer impact
We explored the impact of SARS-CoV-2 proteins on the viability of chronic myeloid leukemia (CML) cells, focusing on the protective role of vitamin K2 (VK2) when used alongside imatinib, a common CML treatment. Our experiments involved K562 CML cell lines to observe how the SARS-CoV-2 envelope protein affects these cancer cells.
What we found was concerning: the virus's protein induced cell damage and activated markers associated with cell death. However, when VK2 was introduced, we noted significant improvements. VK2 not only minimized the cytotoxic effects of the virus but also reduced inflammatory cytokine production. It inhibited the formation of cell colonies, indicating a protective effect on the cancer cells.
We further investigated the synergy between VK2 and imatinib. The combination led to a notable decrease in cell proliferation and disrupted the mitochondrial function of the cancer cells. This suggests that VK2 can enhance the effectiveness of imatinib while providing additional protection against SARS-CoV-2-induced toxicity.
These findings paint a hopeful picture for CML treatment during the ongoing COVID-19 pandemic, leveraging VK2 as a possible adjunctive therapy to protect against viral cell damage while boosting existing treatments.
What we found was concerning: the virus's protein induced cell damage and activated markers associated with cell death. However, when VK2 was introduced, we noted significant improvements. VK2 not only minimized the cytotoxic effects of the virus but also reduced inflammatory cytokine production. It inhibited the formation of cell colonies, indicating a protective effect on the cancer cells.
We further investigated the synergy between VK2 and imatinib. The combination led to a notable decrease in cell proliferation and disrupted the mitochondrial function of the cancer cells. This suggests that VK2 can enhance the effectiveness of imatinib while providing additional protection against SARS-CoV-2-induced toxicity.
These findings paint a hopeful picture for CML treatment during the ongoing COVID-19 pandemic, leveraging VK2 as a possible adjunctive therapy to protect against viral cell damage while boosting existing treatments.
Read More
8
Vitamin K2 enhances cancer treatment
Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
Significant combination treatment findings
We explored the potential of Vitamin K2 (VK2) as a treatment option for chronic myeloid leukemia (CML), particularly in cases where cells have developed resistance to common therapies. The study focused on how VK2 interacts with asciminib, a specialized drug that targets specific challenges faced in treating this type of cancer.
Using a variety of CML cell lines, including those resistant to other medications, we observed that combining VK2 with asciminib led to greater levels of cell inhibition. This combination not only improved cell death rates but also activated key indicators of cellular distress, like caspase activity, which is associated with apoptosis (programmed cell death).
While VK2 alone had shown some anticancer promise, its partnership with asciminib unveiled an enhanced efficacy, making the duo a compelling consideration for those resistant to traditional ABL tyrosine kinase inhibitors (TKIs). This finding holds significant promise for improving treatment outcomes for patients battling resistance in CML.
Using a variety of CML cell lines, including those resistant to other medications, we observed that combining VK2 with asciminib led to greater levels of cell inhibition. This combination not only improved cell death rates but also activated key indicators of cellular distress, like caspase activity, which is associated with apoptosis (programmed cell death).
While VK2 alone had shown some anticancer promise, its partnership with asciminib unveiled an enhanced efficacy, making the duo a compelling consideration for those resistant to traditional ABL tyrosine kinase inhibitors (TKIs). This finding holds significant promise for improving treatment outcomes for patients battling resistance in CML.
Read More
8
Vitamin K2 aids cancer treatment
Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)D in triple negative breast cancer cells.
Relevant to cancer treatment research
We focused on understanding how vitamin K2 might enhance the anti-cancer effects of a well-known treatment, 1,25 dihydroxyvitamin D3 (1,25(OH)D), particularly in aggressive triple negative breast cancer (TNBC) cells. Our research involved several experiments where we treated three different TNBC cell lines with both vitamin K2 and 1,25(OH)D to see how they influenced cell growth, survival, and overall behavior.
Interestingly, we discovered that while each TNBC cell line showed some sensitivity to 1,25(OH)D, the addition of vitamin K2 led to a more significant decrease in cell viability. In particular, we observed that combining these treatments not only increased the number of dead cancer cells but also triggered cell cycle arrest, which is essential for preventing further growth of the tumors.
Moreover, treatment with K2 seemed to change how some of these cells looked and acted, nudging them towards a more differentiated state, which is often a sign of reduced malignancy. In one of the cell lines, K2 even boosted the expression of the vitamin D receptor, suggesting a possible increase in sensitivity to 1,25(OH)D. These effects highlight the complex ways that K2 and 1,25(OH)D can work together to combat cancer.
Overall, our findings point to the potential of vitamin K2 as a valuable ally in cancer treatment, particularly when paired with vitamin D compounds. However, further studies are necessary to unveil the intricate mechanisms at play and how best to utilize these vitamins in therapeutic contexts.
Interestingly, we discovered that while each TNBC cell line showed some sensitivity to 1,25(OH)D, the addition of vitamin K2 led to a more significant decrease in cell viability. In particular, we observed that combining these treatments not only increased the number of dead cancer cells but also triggered cell cycle arrest, which is essential for preventing further growth of the tumors.
Moreover, treatment with K2 seemed to change how some of these cells looked and acted, nudging them towards a more differentiated state, which is often a sign of reduced malignancy. In one of the cell lines, K2 even boosted the expression of the vitamin D receptor, suggesting a possible increase in sensitivity to 1,25(OH)D. These effects highlight the complex ways that K2 and 1,25(OH)D can work together to combat cancer.
Overall, our findings point to the potential of vitamin K2 as a valuable ally in cancer treatment, particularly when paired with vitamin D compounds. However, further studies are necessary to unveil the intricate mechanisms at play and how best to utilize these vitamins in therapeutic contexts.
Read More
8
Vitamin K2-7's potential in cancer
Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities.
Benefits in cancer treatment uncertain
We examined the effects of vitamin K2-7, also known as menaquinone-7, on cancer, focusing on its mechanisms and overall health benefits. Our analysis highlighted that K2-7 may help suppress cancer cell growth through several interesting pathways, including cell-cycle arrest and promoting apoptosis, which is essentially programmed cell death that is crucial for eliminating harmful cells.
Moreover, we observed K2-7's ability to influence certain inflammatory markers, indicating it may play a role in reducing inflammation associated with various cancers. These mechanisms suggest that vitamin K2-7 could be a beneficial supplement alongside traditional cancer treatments, although further research is necessary to fully understand its isolated effects.
While the promising results lean towards its potential, it's essential to note that there have been no definitive claims that vitamin K2-7 is a standalone treatment. Instead, it seems to act as a supportive agent, working alongside other therapies to enhance health outcomes in cancer patients. Overall, we encourage more clinical trials to clarify its role and effectiveness in cancer treatment protocols.
Moreover, we observed K2-7's ability to influence certain inflammatory markers, indicating it may play a role in reducing inflammation associated with various cancers. These mechanisms suggest that vitamin K2-7 could be a beneficial supplement alongside traditional cancer treatments, although further research is necessary to fully understand its isolated effects.
While the promising results lean towards its potential, it's essential to note that there have been no definitive claims that vitamin K2-7 is a standalone treatment. Instead, it seems to act as a supportive agent, working alongside other therapies to enhance health outcomes in cancer patients. Overall, we encourage more clinical trials to clarify its role and effectiveness in cancer treatment protocols.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
8.8
Promotes health overall
I take MK-7 daily to prevent various health issues, including supporting bone density and fighting cancer. I learned about its benefits on the Dr. Oz show, and it has become an essential part of my routine. I appreciate the many advantages it offers to my overall well-being.
